WOCKHARDT RECEIVES THE `BEST ENTERPRISE’ AWARD FROM THE EUROPE BUSINESS ASSEMBLY, OXFORD, GREAT BRITAINThe award is accompanied with a certificate allowing Wockhardt to use the trademark `BEST ENTERPRISE’ for marketing purposes.
Seen here (L-R) Wil Goodheer, President of the International Club of Rector, Dr. Murtaza Khorakiwala, Managing Director, Wockhardt
and Leticia Goodheer, Vice President of the Europe Business Assembly.
Wockhardt is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 7900 Wockhardt Associates from 21 different nationalities globally. It has 3 research centres and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines.
New Wockhardt. New way of thinking.Wockhardt is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and techno-innovation within Wockhardt.
At Wockhardt, we are looking at new ways of thinking, new ways of working and new ways to touch people’s lives.
Building a new WockhardtWockhardt’s Founder Chairman and Group CEO, Dr. Habil Khorakiwala says, “A decade ago, I saw a changing world that I believed would present us with large-scale future opportunities in the field of pharmaceuticals and biotechnology. We steered our business model to leverage our research capabilities in providing innovative solutions and by constantly upgrading our world-class manufacturing facilities. We ventured outside India systematically and positioned ourselves mainly in the European and the US markets, which currently generates over 69% of our revenues.”
Growing presence around the worldHeadquatered in Mumbai, India, Wockhardt has full-fledged operations in the USA, UK, Ireland and France. It also has its marketing presence in emerging markets of Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait.
Spearheading Research & DevelopmentWockhardt’s core business is innovation. It uses science and technology to develop medicines and other products that improve the quality of millions people’s lives through better health.
Wockhardt has proved its technical excellence by developing patented modified release formulations and recombinant biotechnology products. It has a multi-disciplinary R&D programme with more than 578 scientists, including over 80 doctorates, in the areas of:
- Pharmaceutical Research
- Biotechnology & Genomics Research
- Novel Drug Delivery Systems
- New Drug Discovery Programme. API Research
Intellectual PropertyWockhardt is in the forefront of Intellectual Property creation with 1,667 patents filed till date, of which 169 patents have been granted. Our capability and commitment in pursuing Intellectual Property has been recognised by the Government of India for four years in a row, with an award for the maximum number of ‘Patent filings and Grants from India’. Wockhardt is determined to create benchmarks for a promising future.
"Wockhardt has embarked on a new and exciting phase of its growth journey. As a global healthcare company, Wockhardt has proved its technical excellence by developing patented modified release formulations and other complex and challenging medical technologies. We are committed to the pursuit of excellence in business and in society."
Dr. Murtaza Khorakiwala
Making strides through multi-technological advancesWockhardt has vast international expertise in the manufacture of pharmaceuticals and biopharmaceutical formulations as well as Active Pharmaceutical Ingredients (API).
The company has successfully created an integrated multi-technology capability to manufacture all types of dosage forms including sterile injectables and lyophilised products. Highly skilled technicians operate 12 manufacturing facilities that are US FDA, UK MHRA and EMEA compliant sites in India, the US and Europe.
The state-of-the-art biotech plant in Aurangabad has six dedicated manufacturing facilities for biopharmaceutical bulk as well as recombinant formulations. The Wockhardt Biotech Park has created its own benchmark in manufacturing recombinant products with world-class technology.
Creating value through collaborationsWockhardt works with partners to in-license products in India and out-license products into other regions by capitalising on these collaborative strengths to capture and penetrate new markets.
According to Wockhardt’s MD, Dr. Murtaza Khorakiwala, strategic partnerships are a less capital-intensive way of moving into new territories or acquiring new capabilities. By finding partners with complementary skills, Wockhardt endeavours to find smarter ways to grow and in turn create significant value for all its stakeholders.
Corporate Social Responsibility – Sustainability beyond ProfitsWockhardt’s CSR arm under Wockhardt Foundation has touched in a short period of time, 3 million lives through its various medical and social programmes and initiatives. The Foundation is a movement of human values, social awareness and social development.
Determined to Succeed
Wockhardt aspires to create a healthier world. Its strategic vision of ‘More & More with Less & Less’ has transformed into new ways of thinking, a new journey for growth, medical breakthroughs for patients and continuing value for all stakeholders.